Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GMK (Progenics Pharmaceuticals).

Keith L Knutson1

  • 1University of Washington, Tumor Vaccine Group, Seattle, 98195, USA. kknutson@u.washington.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
PubMed
Summary

Progenics Pharmaceuticals is developing the GMK vaccine, a novel ganglioside conjugate vaccine, for melanoma treatment. Clinical trials indicate GMK vaccination may improve survival rates in melanoma patients by inducing antibodies that target cancer cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of tumor-associated antigens with multi-cancer therapeutic potential.

Frontiers in immunology·2026
Same author

Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer.

Journal for immunotherapy of cancer·2026
Same author

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Prognostic Significance, Predictive Value, and Emerging Directions for Clinical Implementation.

Cancers·2026
Same author

Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy.

Frontiers in immunology·2026
Same author

A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

A vaccination strategy to prevent coxsackie virus B3-induced development of pancreatic cancer.

JCI insight·2025

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • Progenics Pharmaceuticals is developing the GMK vaccine, a ganglioside conjugate vaccine, for melanoma and other cancers.
  • The vaccine, licensed from Memorial Sloan-Kettering Cancer Center, was previously co-developed with Bristol-Myers Squibb.
  • GMK is the first in a new class of ganglioside conjugate vaccines evaluated by Progenics.

Purpose of the Study:

  • To evaluate the efficacy of the GMK vaccine in treating melanoma.
  • To assess the potential of GMK vaccination to improve disease-free and overall survival in melanoma patients.

Main Methods:

  • The GMK vaccine is a ganglioside conjugate vaccine coupled to keyhole limpet hemocyanin and formulated with the adjuvant QS-21.
  • Two Phase III clinical trials are underway: one comparing GMK to high-dose IFNalpha in high-risk melanoma patients, and another comparing GMK to close monitoring in patients at immediate risk of relapse.
  • The vaccine induces antibodies against GM2 ganglioside, which are capable of specifically killing melanoma cells.

Main Results:

  • Melanoma patients who develop antibodies against GM2 ganglioside demonstrate significantly improved disease-free and overall survival compared to antibody-negative patients.
  • Financial analysts have projected significant market potential and sales for the GMK vaccine, with estimated launch dates and peak sales figures varying between 2002 and 2006.

Conclusions:

  • GMK vaccination shows promise in improving survival outcomes for melanoma patients.
  • The ongoing Phase III trials are critical for determining the vaccine's ultimate clinical utility and market potential.

Related Experiment Videos